WVC 91st Annual Conference
Appetite is often a key determinant in a pet owners’ perceived quality of life evaluation for their dog or cat with cancer or other chronic disease process. Lack of appetite is often the first recognizable sign by pet owners that their dog or cat is not feeling well and often triggers inquiry to their veterinarian’s office. Inappetence in pets with chronic disease is often multifactorial with potential underlying causes including: cancer, chronic kidney disease, congestive heart failure, inflammatory bowel disease, or secondary to other mediations/treatments, including chemotherapy. Recent availability of capromorelin (ghrelin agonist), an appetite stimulant approved by the FDA for use in dogs, provides a new tool to help manage this important clinical sign. In addition to reviewing the mechanism of action and dosing, practical integration of capromorelin (ENTYCE) for appetite stimulation, quality of life improvement and potential cachexia management in dogs will be outlined with case examples.